NewcelX NCEL
NASDAQ NCEL
$3.26 -0.11 (-3.18%)
As of: Aug 21, 2026 · 1:20 PM EDT

NewcelX (NCEL) Non-Current Deffered Revenue (2019 - 2024)

NewcelX (NCEL) posted quarterly Non-Current Deffered Revenue of $2.5 million for Q4 2024, little changed year-over-year from $2.5 million in Q1 2024, and little changed quarter-over-quarter from $2.5 million in Q2 2024.

NewcelX (NCEL) Non-Current Deffered Revenue (2019 - 2024) Analysis & Trends

NewcelX (NCEL) has reported Non-Current Deffered Revenue for 6 consecutive years, with $2.5 million the latest figure, recorded in Q4 2024.

  • In Q4 2024, Non-Current Deffered Revenue changed 0.0% year-over-year to $2.5 million; the TTM figure through Dec 2024 stood at $2.5 million (changed 0.0% YoY), while the FY2024 annual figure was $2.5 million, changed 0.0% from the prior year.
  • Non-Current Deffered Revenue was little changed at $2.5 million in Q4 2024 per NCEL's latest filing, from $2.5 million in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $2.5 million in Q2 2024 and bottomed at $2.5 million in Q4 2020.
  • Historically, Non-Current Deffered Revenue has averaged $2.5 million across 5 years, with a median of $2.5 million in 2020.
  • Annual changes were most pronounced in 2020 — Non-Current Deffered Revenue changed 0.0% — and 2024, when it climbed 0.0%.
  • NewcelX's Non-Current Deffered Revenue stood at $2.5 million in 2020, then changed by 0.0% to $2.5 million in 2021, then changed by 0.0% to $2.5 million in 2022, then changed by 0.0% to $2.5 million in 2023, then increased by 0.0% to $2.5 million in 2024.
  • Business Quant data shows NCEL's Non-Current Deffered Revenue at $2.5 million in Q4 2024, $2.5 million in Q2 2024, and $2.5 million in Q4 2023.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Deffered Revenue (Qtr)
1 Vertex Pharmaceuticals 139.13 Bn 131.28 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 85.77 Bn 77.77 Bn 3.93 Bn 220.40 Mn
3 Argenx Se 64.64 Bn 59.46 Bn 1.37 Bn -
4 Moderna 58.29 Bn 53.16 Bn 52.00 Mn 147.00 Mn
5 BeOne Medicines 41.92 Bn 36.82 Bn 1.53 Bn -
6 Alnylam Pharmaceuticals 31.58 Bn 28.28 Bn 992.69 Mn -
7 BioNTech SE 28.12 Bn 9.73 Bn 668.28 Mn -
8 Insmed 27.39 Bn 26.22 Bn 358.27 Mn -
9 Royalty Pharma 27.27 Bn 26.43 Bn - -
10 NewcelX 12.54 Mn 10.34 Mn - -

Historic Data

Download Data
DateValue
Dec 31, 2024 2.50 Mn
Jun 30, 2024 2.50 Mn
Dec 31, 2023 2.50 Mn
Jun 30, 2023 2.50 Mn
Dec 31, 2022 2.50 Mn
Jun 30, 2022 2.50 Mn
Dec 31, 2021 2.50 Mn
Jun 30, 2021 2.50 Mn
Dec 31, 2020 2.50 Mn
Dec 31, 2019 2.50 Mn